Point-of-Care Production of CAR-T Cells

[1]  H. Einsele,et al.  CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma , 2021, Gene Therapy.

[2]  A. Wick,et al.  Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR , 2020, Cancers.

[3]  M. Juan,et al.  Cell Banking of HEK293T cell line for clinical-grade lentiviral particles manufacturing , 2020, Translational Medicine Communications.

[4]  S. Rives,et al.  Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial , 2020, Frontiers in Immunology.

[5]  P. Dreger,et al.  Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients , 2020, Molecular therapy. Methods & clinical development.

[6]  L. Sellner,et al.  Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells , 2019, Cancer Immunology, Immunotherapy.

[7]  A. Ho,et al.  Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol , 2019, BMJ Open.

[8]  M. Lowdell,et al.  Manufacturing chimeric antigen receptor T cells: issues and challenges. , 2019, Cytotherapy.

[9]  S. Rives,et al.  Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions , 2018, Molecular therapy. Methods & clinical development.

[10]  A. Ho,et al.  Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients , 2018, Front. Immunol..